Evidence map›Paper›PMID 33643466›Full record

ArticleCellular and molecular bioengineering2021

Pre-existing Cell States Control Heterogeneity of Both EGFR and CXCR4 Signaling.

Phillip C Spinosa, Patrick C Kinnunen, Brock A Humphries, Gary D Luker, Kathryn E Luker, Jennifer J Linderman

Open access · greenAbstract read
In one paragraph

Article in Cellular and molecular bioengineering, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. TheCells · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Phillip C SpinosaDepartment of Chemical Engineering, University of Michigan, 2800 Plymouth Road, Ann Arbor, MI 48109-2800 USA.ORCID 0000-0002-9353-9085
Patrick C KinnunenDepartment of Chemical Engineering, University of Michigan, 2800 Plymouth Road, Ann Arbor, MI 48109-2800 USA.
Brock A HumphriesDepartment of Radiology Center for Molecular Imaging, University of Michigan Medical School, Ann Arbor, MI 48109 USA.
Gary D LukerDepartment of Radiology Center for Molecular Imaging, University of Michigan Medical School, Ann Arbor, MI 48109 USA.
Kathryn E LukerDepartment of Radiology Center for Molecular Imaging, University of Michigan Medical School, Ann Arbor, MI 48109 USA.
Jennifer J LindermanDepartment of Chemical Engineering, University of Michigan, 2800 Plymouth Road, Ann Arbor, MI 48109-2800 USA.ORCID 0000-0002-1519-5088
University of Michigan · US

Funding

Interstitial Fluid Flow Regulates Glioma Cell InvasionR37CA222563 · NCI · VIRGINIA POLYTECHNIC INST AND ST UNIV · PI MUNSON, JENNIFER M · 2018 to 2024
$4.0M
Microfluidics in Biomedical Sciences Training ProgramT32EB005582 · NIBIB · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI FAN, XUDONG · 2005 to 2020
$3.9M
Environmental Regulation of Cancer Stem Cell Plasticity in MetastasisU01CA210152 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LAHANN, JOERG, LUKER, GARY D · 2017 to 2021
$3.6M
University of Michigan Quantitative Co-Clinical Imaging Research ResourceU24CA237683 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHENEVERT, THOMAS L, LUKER, GARY D · 2019 to 2023
$3.1M
Imaging Disease Heterogeneity and Response to Therapy in MyelofibrosisR01CA238023 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LUKER, GARY D, ROSS, BRIAN D. · 2019 to 2023
$3.1M
Integrators of Metastatic PotentialR01CA238042 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GHOSH, PRADIPTA, LUKER, GARY D · 2019 to 2023
$2.3M
Systems Bioengineering of Cancer Cell MigrationR01CA196018 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LINDERMAN, JENNIFER JEAN, LUKER, GARY D · 2015 to 2019
$2.2M
Specialist in Multi-Scale Molecular Imaging of Tumor EnvironmentsR50CA221807 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Kathryn Luker · 2018 to 2026
$1.6M
A High Throughput Human Tumor Modeling Technology for Cancer Drug DiscoveryR33CA225549 · NCI · UNIVERSITY OF AKRON · PI LUKER, GARY D, TAVANA, HOSSEIN · 2019 to 2021
$1.4M
NCI NIH HHS R01 CA196018NCI NIH HHS R01 CA238023NCI NIH HHS R01 CA238042NCI NIH HHS R33 CA225549NCI NIH HHS R37 CA222563NCI NIH HHS R50 CA221807NCI NIH HHS U01 CA210152NCI NIH HHS U24 CA237683NIBIB NIH HHS T32 EB005582
6 · The paper itself

Abstract

introductionCXCR4 and epidermal growth factor receptor (EGFR) represent two major families of receptors, G-protein coupled receptors and receptor tyrosine kinases, with central functions in cancer. While utilizing different upstream signaling molecules, both CXCR4 and EGFR activate kinases ERK and Akt, although single-cell activation of these kinases is markedly heterogeneous. One hypothesis regarding the origin of signaling heterogeneity proposes that intercellular variations arise from differences in pre-existing intracellular states set by extrinsic noise. While pre-existing cell states vary among cells, each pre-existing state defines deterministic signaling outputs to downstream effectors. Understanding causes of signaling heterogeneity will inform treatment of cancers with drugs targeting drivers of oncogenic signaling.

methodsWe built a single-cell computational model to predict Akt and ERK responses to CXCR4- and EGFR-mediated stimulation. We investigated signaling heterogeneity through these receptors and tested model predictions using quantitative, live-cell time-lapse imaging.

resultsWe show that the pre-existing cell state predicts single-cell signaling through both CXCR4 and EGFR. Computational modeling reveals that the same set of pre-existing cell states explains signaling heterogeneity through both EGFR and CXCR4 at multiple doses of ligands and in two different breast cancer cell lines. The model also predicts how phosphatidylinositol-3-kinase (PI3K) targeted therapies potentiate ERK signaling in certain breast cancer cells and that low level, combined inhibition of MEK and PI3K ablates potentiated ERK signaling.

conclusionsOur data demonstrate that a conserved motif exists for EGFR and CXCR4 signaling and suggest potential clinical utility of the computational model to optimize therapy.

Indexed as

Computational modelingHeterogeneityKinaseMolecular imagingSingle cell

Identifiers

PMID33643466
PMCPMC7878609
OpenAlexW3045883177

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.